204 related articles for article (PubMed ID: 38380327)
41. A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report.
Zeng H; Liu Y; Wang W; Tang Y; Tian P; Li W
Ann Palliat Med; 2021 Jul; 10(7):8352-8357. PubMed ID: 33832282
[TBL] [Abstract][Full Text] [Related]
42. Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients.
Hua G; Zhang X; Zhang M; Wang Q; Chen X; Yu R; Bao H; Liu J; Wu X; Shao Y; Liang B; Lu K
ESMO Open; 2022 Feb; 7(1):100337. PubMed ID: 35123209
[TBL] [Abstract][Full Text] [Related]
43. Treatment with Next-Generation ALK Inhibitors Fuels Plasma
Dagogo-Jack I; Rooney M; Lin JJ; Nagy RJ; Yeap BY; Hubbeling H; Chin E; Ackil J; Farago AF; Hata AN; Lennerz JK; Gainor JF; Lanman RB; Shaw AT
Clin Cancer Res; 2019 Nov; 25(22):6662-6670. PubMed ID: 31358542
[TBL] [Abstract][Full Text] [Related]
44. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Remon J; Pignataro D; Novello S; Passiglia F
Cancer Treat Rev; 2021 Apr; 95():102178. PubMed ID: 33743408
[TBL] [Abstract][Full Text] [Related]
45. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
46. Proteasome Inhibition Overcomes ALK-TKI Resistance in
Tanimoto A; Matsumoto S; Takeuchi S; Arai S; Fukuda K; Nishiyama A; Yoh K; Ikeda T; Furuya N; Nishino K; Ohe Y; Goto K; Yano S
Clin Cancer Res; 2021 Mar; 27(5):1410-1420. PubMed ID: 33310890
[TBL] [Abstract][Full Text] [Related]
47. Transformation of invasive lung adenocarcinoma with ALK rearrangement into pulmonary sarcomatoid carcinoma.
Xie X; Chen X; Luo N; Qi Y; Li M; Feng X
J Cancer Res Clin Oncol; 2022 Aug; 148(8):2165-2168. PubMed ID: 35426613
[TBL] [Abstract][Full Text] [Related]
48. Lung adenocarcinoma with EGFR 19Del and an ALK rearrangement benefits from alectinib instead of an EGFR-TKI: A case report.
Wang H; Zhu S; Li Z; Qi X; Zhang L; Ke L; Lin Y
Medicine (Baltimore); 2022 Sep; 101(35):e30316. PubMed ID: 36107507
[TBL] [Abstract][Full Text] [Related]
49. First-line crizotinib therapy is effective for a novel SEC31A-anaplastic lymphoma kinase fusion in a patient with stage IV lung adenocarcinoma: a case report and literature reviews.
Wu R; Liu S; Lv G; Deng C; Wang R; Zhang S; Zhu D; Wang L; Lei Y; Luo Z
Anticancer Drugs; 2023 Feb; 34(2):294-301. PubMed ID: 36730620
[TBL] [Abstract][Full Text] [Related]
50. Anti-Angiogenic Therapy in
Tan AC; Pavlakis N
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012123
[TBL] [Abstract][Full Text] [Related]
51. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
[TBL] [Abstract][Full Text] [Related]
52. Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion.
Yin Q; Guo T; Zhou Y; Sun L; Meng M; Ma L; Wang X
Thorac Cancer; 2022 Feb; 13(4):637-642. PubMed ID: 34964276
[TBL] [Abstract][Full Text] [Related]
53. A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib.
Matsumura Y; Inomata S; Yamaguchi H; Mine H; Takagi H; Watanabe M; Ozaki Y; Yamaura T; Fukuhara M; Muto S; Okabe N; Hasegawa T; Shio Y; Suzuki H
Thorac Cancer; 2021 Aug; 12(15):2225-2228. PubMed ID: 34159737
[TBL] [Abstract][Full Text] [Related]
54. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
[TBL] [Abstract][Full Text] [Related]
55. Response to ALK-TKIs in a lung adenocarcinoma patient harboring dual DCTN1-ALK and ALK-CLIP4 rearrangements.
Gao F; Gao F; Wu H; Lu J; Xu Y; Zhao Y
Thorac Cancer; 2022 Apr; 13(7):1088-1090. PubMed ID: 35212154
[TBL] [Abstract][Full Text] [Related]
56. Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.
Woo CG; Seo S; Kim SW; Jang SJ; Park KS; Song JY; Lee B; Richards MW; Bayliss R; Lee DH; Choi J
Ann Oncol; 2017 Apr; 28(4):791-797. PubMed ID: 28039177
[TBL] [Abstract][Full Text] [Related]
57. Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study.
Kang J; Deng QM; Peng KC; Li P; Zhu BT; Wang P; Chu XP; Zhong WZ; Chen HJ; Wang WX; Chen HF; Rao CZ; Xu CW; Yang JJ
Genes Chromosomes Cancer; 2022 Apr; 61(4):177-186. PubMed ID: 34687488
[TBL] [Abstract][Full Text] [Related]
58. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).
Golding B; Luu A; Jones R; Viloria-Petit AM
Mol Cancer; 2018 Feb; 17(1):52. PubMed ID: 29455675
[TBL] [Abstract][Full Text] [Related]
59. Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.
Liang Q; Xu H; Liu Y; Zhang W; Sun C; Hu M; Zhu Y; Tan S; Xu X; Wang S; Liu L
Lung Cancer; 2021 Dec; 162():86-89. PubMed ID: 34763158
[TBL] [Abstract][Full Text] [Related]
60. Clinical characteristics and risk factors of drug-induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis.
Koshikawa K; Terada J; Abe M; Iwasawa S; Sakayori M; Yoshioka K; Hirasawa Y; Kasai H; Kawasaki Y; Tsushima K; Tatsumi K
Thorac Cancer; 2020 Jun; 11(6):1495-1502. PubMed ID: 32237210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]